Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
USAT February Reserve Report: Circulating Supply Exceeds 19 Million, Over-collateralization Amount Grows 40% Month-on-Month

USAT February Reserve Report: Circulating Supply Exceeds 19 Million, Over-collateralization Amount Grows 40% Month-on-Month

ForesightNewsForesightNews2026/03/30 14:29
Show original

Foresight News reports that Anchorage Digital Bank has released its USAT reserve report for the period ending February 28, 2026. According to the report, the USAT circulation is 19,001,496 tokens, an increase of 1,500,105 tokens compared to January. The total value of reserve assets is 19,146,639 USD, an increase of approximately 1.54 million USD month-on-month. The report shows that the reserves exceed the circulation by about 145,000 USD, with the excess collateral increasing by 40% compared to the previous period.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Profit surges 7-fold, revenue breaks 100 trillions for the first time: SK hynix (SKHY.US) responds to AI bubble concerns with record-breaking quarterly report

SK Hynix reported an operating profit of 83.3 trillion won for the third quarter, surpassing expectations, and announced shareholder returns of approximately 100 trillion won within the year.

智通财经•2026/10/28 00:37
Profit surges 7-fold, revenue breaks 100 trillions for the first time: SK hynix (SKHY.US) responds to AI bubble concerns with record-breaking quarterly report

AstraZeneca (AZN.US) CEO hints at entry into cancer vaccines: years of experience with mRNA technology and more updates expected in the coming months

AstraZeneca is considering developing a cancer vaccine, with the CEO stating that the company has already accumulated experience in mRNA technology. Personalized vaccines have reduced the recurrence rate of melanoma by 42%, but cost and production capacity remain obstacles to broader adoption.

智通财经•2026/10/28 00:17
AstraZeneca (AZN.US) CEO hints at entry into cancer vaccines: years of experience with mRNA technology and more updates expected in the coming months